Maplight Therapeutics Common Stock Performance
| MPLT Stock | 16.77 0.80 4.55% |
The company secures a Beta (Market Risk) of 0.73, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, MapLight Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding MapLight Therapeutics is expected to be smaller as well. At this point, MapLight Therapeutics has a negative expected return of -0.0046%. Please make sure to verify MapLight Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if MapLight Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days MapLight Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable essential indicators, MapLight Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return (4.53) | Five Day Return (6.83) | Ten Year Return (8.56) | All Time Return (8.56) |
1 | Roundup Pharma Funding Continues with Financing Rounds and Public Offering Price Announcements - PharmExec.com | 10/28/2025 |
2 | MapLight Therapeutics Closes Successful IPO and Private Placement - MSN | 10/30/2025 |
3 | Maplight Therapeutics Hits New 1-Year Low Heres What Happened | 11/26/2025 |
4 | MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress | 12/04/2025 |
5 | Maplight Therapeutics Raised to Hold at Wall Street Zen | 12/22/2025 |
MapLight Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,834 in MapLight Therapeutics Common on October 6, 2025 and sell it today you would lose (157.00) from holding MapLight Therapeutics Common or give up 8.56% of portfolio value over 90 days. MapLight Therapeutics Common is currently does not generate positive expected returns and assumes 6.3736% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than MapLight, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MapLight Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MapLight Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MapLight Therapeutics Common, and traders can use it to determine the average amount a MapLight Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -7.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MPLT |
Based on monthly moving average MapLight Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MapLight Therapeutics by adding MapLight Therapeutics to a well-diversified portfolio.
About MapLight Therapeutics Performance
Assessing MapLight Therapeutics' fundamental ratios provides investors with valuable insights into MapLight Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MapLight Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.61) | (0.64) |
Things to note about MapLight Therapeutics performance evaluation
Checking the ongoing alerts about MapLight Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MapLight Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MapLight Therapeutics generated a negative expected return over the last 90 days | |
| MapLight Therapeutics has high historical volatility and very poor performance | |
| Latest headline from thelincolnianonline.com: Maplight Therapeutics Raised to Hold at Wall Street Zen |
- Analyzing MapLight Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MapLight Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining MapLight Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MapLight Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MapLight Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MapLight Therapeutics' stock. These opinions can provide insight into MapLight Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MapLight Stock Analysis
When running MapLight Therapeutics' price analysis, check to measure MapLight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MapLight Therapeutics is operating at the current time. Most of MapLight Therapeutics' value examination focuses on studying past and present price action to predict the probability of MapLight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MapLight Therapeutics' price. Additionally, you may evaluate how the addition of MapLight Therapeutics to your portfolios can decrease your overall portfolio volatility.